April 10, 2021

Breaking Down Canopy Supreme Deal | Midas Letter RAW ft Wolf Street & PureK (PKAN)

The trading week ended on a high as we saw record closes across the S&P 500, NASDAQ, the DOW, Russel 2000, and the VIX. A third straight week we have enjoyed a market lift as we approach quarterly earnings week – starting Monday.

It would be smart for short-term traders to exhibit a bit of caution with the chance of consolidation after some good weeks, but the markets, in general, are looking as healthy as a person with the vaccine.

As usual, we delve into the latest cannabis market news. Breaking down Canopy Growth‘s (NASDAQ:CGC) (TSE:WEED) acquisition of Supreme Cannabis (OTCMKTS:SPRWF) (TSE:FIRE) and much more.

Midas Letter RAW is the irreverent/intelligent show about investing for the little guy. A former stockbroker and reformed accountant, Ed Milewski, brings his expert but off-beat technical chart observations into focus. At the same time, investment writer James West offers plain language critique of the machinations, shenanigans, and subterfuge foisted on retail investors by the institutions we call capital markets.

We have two exclusive interviews on deck in today’s episode:

1.Wolf Richter, the founder and publisher of the finance/economics site WOLF STREET. Wolf dissects economic, business, and financial data, Wall Street shenanigans, complex entanglements, debacles, and opportunities. He and James share lots of opinions the mainstream media don’t want to report. Definitely a must-watch interview!

2. PureK Holdings Corp (OTCMKTS:PKANF) (CVE:PKAN) CEO Kathy Casey – The ticker pronounced after your favourite nut, pecan, manufactures and sells hemp-based cannabidiol (CBD) related products in the United States. The company has made numerous acquisitions within the last month which expands its product lines (the most notable: PureKana) into other market segments like skincare and pet wellness.

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.